Fig. 1

Genotype and immunophenotype of RET-rearranged lung cancers. aRET upstream fusion partner. b Genomic alterations of patients with RET-positive NSCLC at the time they were diagnosed indicate that RET-rearrangement is mutually exclusive with common driver alterations. c Number of mutations of RET-rearranged lung cancers compared with ALK/ROS1/EGFR-altered lung cancers and RET/ALK/ROS1/EGFR-negative lung cancers. d PD-L1 expression in RET-positive NSCLC. Abbreviations: TMB - tumor mutation burden